The partnership between the biopharma company and CDMO is expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.
The new site precedes the opening of a Yokohama manufacturing facility slated to be operational in 2027 with services for biologics, cell therapies, and messenger RNA.